… merely putting out existing fires. Although the global beauty care firm operates with a lead independent director ( Fred Hassan ), we doubt whether the board is as independent as it may at first appear, given that the average tenure of directors …
… Whenever shareholders bemoan the fate of their investment in this or that drugmaker, invariably someone mentions that Fred Hassan should become CEO. Why? Fred has a brief, if controversial track record of running companies and then selling them …
Even though Richard Kogan is out and Fred Hassan is in at Schering-Plough, we're not ready to post a fair value estimate. Pharmacia's Fred Hassan has taken the top job at Schering-Plough, as expected …
… offset the weakness in its cholesterol franchise and maximize the profit potential from the Organon acquisition. CEO Fred Hassan and his management team successfully restructured the company when faced with the loss of allergy drug Claritin several …
… for a 30% discount before considering them. The company's near-term restructuring plans held few surprises. CEO Fred Hassan has recruited numerous senior managers from outside the company (mostly from Hassan's legacy, Pharmacia) and initiated …
… combination of products and financial wherewithal to rebuild, in our opinion. New leadership is also key, and new CEO Fred Hassan understands this. He's set in motion the necessary changes for a turnaround. He replaced senior management with …
… erosion will be clearer after second-quarter earnings are released July 23. Despite the company's troubles, we think Fred Hassan 's management changes combined with strong Zetia sales could be enough to rescue Schering-Plough from the smoldering …
… came from, so financially, it can take the blow. Even so, we think Schering-Plough is a toxic stock until new CEO Fred Hassan has exorcised the company's demons. We'd look elsewhere.
… our rating on Schering-Plough--management's secretive and shareholder-unfriendly nature--is evaporating as Fred Hassan puts familiar faces in the top jobs. We're keeping some management risk in our valuation, however, until Hassan …
… ago quarter. Sales were down 26%, earnings per share were down 71%, and margins declined. Newly elected CEO Fred Hassan announced several changes in management and the reporting structure, but it will take a while to determine if these …